CRESCENT PHARMA LIMITED
Get an alert when CRESCENT PHARMA LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-01-15 (in 8mo)
Last made up 2026-01-01
Watchouts
None on the register
Cash
£3M
-58.5% vs 2020
Net assets
£23M
+5.7% vs 2020
Employees
55
-19.1% vs 2020
Profit before tax
£349K
-97.2% vs 2020
Net assets
4-year trend · vs Health Care median
Accounts
4-year trend · latest reflected 2021-12-31
Latest accounts filed cover 2024-12-31; financial figures currently reflect up to 2021-12-31.
| Metric | Trend | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Turnover | — | — | £105,278,067 | £96,475,385 | |
| Operating profit | — | — | £12,630,548 | £448,557 | |
| Profit before tax | — | — | £12,539,557 | £349,331 | |
| Net profit | — | — | £10,178,876 | £1,253,649 | |
| Cash | — | — | £7,202,318 | £2,991,505 | |
| Total assets less current liabilities | — | — | £22,057,861 | £23,258,108 | |
| Net assets | — | — | £21,938,106 | £23,191,755 | |
| Equity | £21,278,553 | £11,759,230 | £21,938,106 | £23,191,755 | |
| Average employees | — | — | 68 | 55 | |
| Wages | — | — | — | £2,121,305 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating margin | — | — | 12.0% | 0.5% | |
| Net margin | — | — | 9.7% | 1.3% | |
| Return on capital employed | — | — | 57.3% | 1.9% | |
| Interest cover | — | — | 132.61x | 4.52x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Menzies LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Group structure
- CRESCENT PHARMA LIMITED · parent
- Crescent Pharma OTC Limited 100%
Significant events
- “On 4 July 2025, the company completed the purchase of a warehouse for a total consideration of £26,000,000. The agreement to purchase was signed after the balance sheet date.”
- “On 24 January 2025, Crescent Pharma Australia Pty Ltd was incorporated in Australia with its registered office at Level 2, 115 Pitt Street, Sydney, New South Wales, 2000. This new entity is a wholly owned subsidiary of Crescent Pharma Limited. The entity has been established to hold marketing authorisations in Australia and is not currently undertaking any operational activities.”
- “The company has continued with significant investment in research and development to add to it's product range.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 6 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| AL-DOORI, Mohammed Khalid | Director | 2003-05-01 | Nov 1965 | British |
| ALDOORI, Laith Khalid | Director | 2023-06-07 | Dec 1989 | British |
| ALDOORI, Samie Mohammed | Director | 2023-06-07 | Aug 1991 | British |
Show 6 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BARTLETT, Margaret Mary | Secretary | 2003-05-01 | 2004-03-26 |
| ACORN ACCOUNTING SOLUTIONS LTD | Corporate Secretary | 2004-03-26 | 2009-03-31 |
| BRIGHTON SECRETARY LTD | Corporate Nominee Secretary | 2003-05-01 | 2003-05-06 |
| AUCHI, Luma | Director | 2003-05-01 | 2010-02-12 |
| MALONE, Gerald | Director | 2003-05-01 | 2010-02-12 |
| BRIGHTON DIRECTOR LTD | Corporate Nominee Director | 2003-05-01 | 2003-05-06 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Crescent Pharmaceuticals Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2024-01-29 | Active |
| Mr Mohammed Khalid Aldoori | Individual | Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 97 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-01-14 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-07 | AA | accounts | Accounts with accounts type full | |
| 2025-07-07 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-01-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-12 | AA | accounts | Accounts with accounts type full | |
| 2024-06-26 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-04-16 | RESOLUTIONS | resolution | Resolution | |
| 2024-04-12 | MA | incorporation | Memorandum articles | |
| 2024-04-05 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-04-05 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-04-05 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-04-04 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2024-01-30 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2024-01-09 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-10-27 | AA | accounts | Accounts with accounts type full | |
| 2023-06-20 | AP01 | officers | Appoint person director company with name date | |
| 2023-06-20 | AP01 | officers | Appoint person director company with name date | |
| 2023-01-12 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-12-23 | AA | accounts | Accounts with accounts type full | |
| 2022-05-03 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2020 → FY2021 · period ending 2021-12-31 vs 2020-12-31
-
Turnover
-8.4%
£105,278,067 £96,475,385
-
Cash
-58.5%
£7,202,318 £2,991,505
-
Net assets
+5.7%
£21,938,106 £23,191,755
-
Employees
-19.1%
68 55
-
Operating profit
-96.4%
£12,630,548 £448,557
-
Profit before tax
-97.2%
£12,539,557 £349,331
Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers